Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane

被引：0
|
作者：
Mavinkurve-Groothuis, Annelies M. C. [1 ]
de Baat, Esmee C. [1 ]
Feijen, Elizabeth A. M. [1 ]
Kremer, Leontien C. M. [1 ,2 ,3 ]
Armenian, Saro H. [4 ]
Mulder, Renee L. [1 ]
van Dalen, Elvira C. [1 ]
机构：
[1] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Cardiol, Utrecht, Netherlands
[3] Univ Amsterdam, Emma Childrens Hosp, Amsterdam UMC, Amsterdam, Netherlands
[4] City Hope Natl Med Ctr, Natl Med Ctr, Populat Sci, Duarte, CA USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷 / 10期
关键词：
D O I：
10.1002/pbc.30604
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CARDIOTOXICITY PHENOTYPES IN WOMEN TREATED WITH ANTHRACYCLINES AND TRASTUZUMAB FOR EARLY STAGE BREAST CANCER
    Nolan, Mark T.
    Selam, Mustafa Abdul
    Amir, Eitan
    Koch, Anne
    Yip, Paul
    Michalowska, Maria
    Wintersperger, Bernd
    Thavendiranathan, Paaladinesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 799 - 799
  • [22] Dexrazoxane prevents doxorubicin-induced cardiotoxicity in children
    Reactions Weekly, 2004, 1010 (1) : 3 - 3
  • [23] Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
    Choi, Hyoung Soo
    Park, Eun Sil
    Kang, Hyoung Jin
    Shin, Hee Young
    Noh, Chung Il
    Yun, Yong Soo
    Ahn, Hyo Seop
    Choi, Jung Yun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (09) : 1336 - 1342
  • [24] DEXRAZOXANE FOR PROTECTION OF ANTHRACYCLINE CARDIOTOXICITY IN CHILDREN WITH SOLID TUMORS
    Choi, Hyoungsoo
    Kang, Hyoung Jin
    Shin, Hee Young
    Seo, Jong Jin
    Ahn, Hyo Seop
    Choi, Jung Yon
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 735 - 736
  • [25] Late cardiotoxicity of anthracyclines in children with acute leukemia
    Zalewska-Szewczyk, B
    Lipiec, J
    Bodalski, J
    KLINISCHE PADIATRIE, 1999, 211 (04): : 356 - 359
  • [26] The Efficacy of Dexrazoxane to Prevent Early Cardiotoxicity in Children with Cancer: A Population-Based Study
    DeWaard, D.
    Kulkarni, K.
    Warren, A.
    MacDonald, T.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S520 - S520
  • [27] FUNCTIONAL MYOCARDIAL IMPAIRMENT IN CHILDREN TREATED WITH ANTHRACYCLINES FOR CANCER
    YEUNG, ST
    YOONG, C
    SPINK, J
    GALBRAITH, A
    SMITH, PJ
    LANCET, 1991, 337 (8745): : 816 - 818
  • [28] Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines
    Pouillart, P
    CANCER TREATMENT REVIEWS, 2004, 30 (07) : 643 - 650
  • [29] Malnutrition as Risk Factor for Anthracyclines-Induced Cardiotoxicity in Mexican Children with Cancer
    Vargas-Neri, J. L.
    Castelan-Martinez, O. D.
    Rivas-Ruiz, R.
    Rodriguez-Islas, F.
    Rios-Arroy, A. I.
    DRUG SAFETY, 2016, 39 (10) : 996 - 996
  • [30] Role of metabolomics in the identification of early patterns of cardiotoxicity in patients with breast cancer treated with anthracyclines
    Pinna, Gabriele
    Aneris, Federico
    Agus, Elena
    Demelas, Roberta
    Peccianti, Antonella
    Pettinau, Antonio
    Zanda, Greca
    Noto, Antonio
    Fattuoni, Claudia
    Deidda, Martino
    Atzori, Francesco
    Madeddu, Clelia
    Scartozzi, Mario
    Mercuro, Giuseppe
    Dessalvi, Christian Cadeddu
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N19 - N20
12345